Cardiomyopathy Clinical Trials

26 recruiting

Cardiomyopathy Trials at a Glance

233 actively recruiting trials for cardiomyopathy are listed on ClinicalTrialsFinder across 6 cities in 53 countries. The largest study group is Not Applicable with 56 trials, with the heaviest enrollment activity in Boston, New York, and Cleveland. Lead sponsors running cardiomyopathy studies include Bristol-Myers Squibb, China National Center for Cardiovascular Diseases, and Shandong Suncadia Medicine Co., Ltd..

Browse cardiomyopathy trials by phase

Treatments under study

About Cardiomyopathy Clinical Trials

Looking for clinical trials for Cardiomyopathy? There are currently 26 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Cardiomyopathy trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Cardiomyopathy clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 233 trials

Recruiting

Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular System

ObesityCardiomyopathyLi-Fraumeni Syndrome+3 more
National Heart, Lung, and Blood Institute (NHLBI)5,000 enrolled3 locationsNCT01143454
Recruiting
Phase 4

A Study to Learn More About the Change in the Blood Levels of Transthyretin When Participants With Transthyretin Amyloidosis With Cardiomyopathy Switch From Tafamidis to Acoramidis

Transthyretin Amyloid Cardiomyopathy
Bayer50 enrolled10 locationsNCT07298044
Recruiting
Not Applicable

Is There a Genetic Predisposition for Acute Stress-induced (Takotsubo) Cardiomyopathy

Takotsubo Cardiomyopathy
University of Aberdeen700 enrolled2 locationsNCT04513054
Recruiting
Phase 2

Cyclosporine In Takotsubo Syndrome

Takotsubo Cardiomyopathy
University Hospital Heidelberg204 enrolled24 locationsNCT05946772
Recruiting
Phase 2Phase 3

A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy

Symptomatic Genetic Dilated Cardiomyopathy
Kardigan, Inc.332 enrolled33 locationsNCT07210723
Recruiting

Multicentre Hypertrophic Cardiomyopathy Registry

Hypertrophic Cardiomyopathy (HCM)
University of Manchester2,500 enrolled1 locationNCT07381894
Recruiting
Phase 2

A Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in Patients With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy

Non-obstructive Hypertrophic Cardiomyopathy
Imbria Pharmaceuticals, Inc.165 enrolled56 locationsNCT07023614
Recruiting

A Retrospective Observational Study of Epidemiology and Outcomes in Transthyretin Amyloid Cardiomyopathy in Germany

ATTR-CM (Transthyretin Amyloid Cardiomyopathy)
Pfizer1 enrolled1 locationNCT07494656
Recruiting

Mavacamten Outcomes in Hypertrophic Cardiomyopathy (HCM) and the Associated Patient and Physician Experiences in the US

Obstructive Hypertrophic Cardiomyopathy (oHCM)
Bristol-Myers Squibb362 enrolled1 locationNCT07557498
Recruiting

DemonsTTRate: A Global, Observational, Multicenter, Long-term Study of Patients With ATTR-CM in a Real-World Setting

Transthyretin Amyloidosis With Cardiomyopathy
Alnylam Pharmaceuticals2,000 enrolled4 locationsNCT07358078
Recruiting
Phase 3

CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis

Transthyretin Amyloid Cardiomyopathy (ATTR CM)
Novo Nordisk A/S1,280 enrolled289 locationsNCT07207811
Recruiting

Mayo AVC Registry and Biobank

CardiomyopathiesCardiovascular DiseasesHeart Diseases+5 more
Mayo Clinic1,000 enrolled2 locationsNCT03049254
Recruiting
Not Applicable

RestoratIon of Myocardial Function by PeRcutaneous cOronary interVEntion in Patients With Ischemic CardioMyoPathy

Ischemic Cardiomyopathy
Seoul National University Hospital158 enrolled1 locationNCT06930092
Recruiting

KIDSHEART AND BRAIN : Early EEG Surgery Congenital Heart Disease Predict Onset of Neurodevelopmental Disorders

Neurodevelopmental DisordersCongenital Cardiomyopathy
University Hospital, Lille50 enrolled1 locationNCT05658965
Recruiting
Phase 3

TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

Transthyretin Amyloidosis With Cardiomyopathy
Alnylam Pharmaceuticals1,250 enrolled207 locationsNCT07052903
Recruiting
Phase 3

CMP-MYTHiC Trial and Registry - CardioMyoPathy With MYocarditis THerapy With Colchicine

Heart FailureCardiomyopathiesMyocarditis+2 more
Niguarda Hospital80 enrolled10 locationsNCT06158698
Recruiting

A Study Of Deep Learning For Echo Analysis, Tracking, And Evaluation

CardiomyopathyCardiac AmyloidosisIschemic Heart Disease
Mayo Clinic10,040,000 enrolled1 locationNCT07308704
Recruiting

Effectiveness and Treatment Patterns of Mavacamten in Patients With Obstructive Hypertrophic Cardiomyopathy in Japan (MANAGE-HCM)

Cardiomyopathy
Bristol-Myers Squibb36 enrolled1 locationNCT07541833
Recruiting
Phase 1

A Bioequivalence Study of Two Formulations of HRS-1893 Tablets in Healthy Participants

Cardiomyopathy
Shandong Suncadia Medicine Co., Ltd.36 enrolled1 locationNCT07479641
Recruiting
Phase 2

Evaluation of the Possible Safety and Efficacy of Dapagliflozin in the Prophylaxis of Doxorubicin-Induced Cardiotoxicity

Breast CancerDoxorubicin Induced Cardiomyopathy
Tanta University46 enrolled1 locationNCT06427226